Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06508463 · ClinicalTrials.gov registry record · Phase 1
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
A Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT06508463: Recruiting Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Mayo Clinic.
NCT06508463 is a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 21 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06508463, a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
Assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 1 |
What NCT06508463 shows while recruiting
NCT06508463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (80% lower).
The record links to 7 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06508463 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06508463 about?
NCT06508463 is a clinical study titled "Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma". This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, ...
What is the current status of trial NCT06508463?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2024-01-05. Estimated completion is 2032-04-01.
What conditions does trial NCT06508463 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Relapsed Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT06508463?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT06508463?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06508463 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06508463's enrollment target sits among peer trials
21 24th of 34 higher than 10 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Evaluate the Safety and Clinical Activity of HH2853
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI